Meduloc has raised $4.0M in a Series B round, with backing from GenHenn Capital, Life Sciences Greenhouse Investments, Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, and Andre Ethier.
The company’s implant is designed to treat small, long bone fractures-think metacarpals, metatarsals, and clavicles-using a flexible intramedullary device that offers fracture reduction and rotational stability while sparing soft tissue and articular cartilage. That’s a meaningful pitch for surgeons who want a less invasive option than traditional plating, and the round suggests investors see traction in that niche.


















